0398 Impact of an Over-The-Counter "Sleep Lotion" on Salivary Melatonin Levels and Sleep Quality

Clairissa Ponce,Amanda Razon,Joey Chao,Sydney Nakagawa,Megan Peterson,Angelina Roque,Maya Vanderpool,Michael Ferracane,Lisa Olson
DOI: https://doi.org/10.1093/sleep/zsae067.0398
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Many over-the-counter products such as bubble baths, room sprays, and lotions claim they contain the pineal hormone melatonin and promote sleep. In this randomized, controlled, double-blind crossover trial we compared the impact of a commercial “sleep lotion” versus a placebo control lotion. Methods Participants applied lotions on two different nights, one hour before bedtime. To assess whether melatonin was absorbed through the skin and circulating systemically, we conducted enzyme linked immunosorbent assays on saliva samples to quantitate melatonin levels. We also assessed sleep quality the night after lotion application with a modified Pittsburgh Sleep Quality Index. The amount of melatonin in Dr. Teal’s Sleep Lotion was measured using High Performance Liquid Chromatography. Results Our sample of 63 undergraduate college students scored an average of 6.3 ± 2.7 on the Global Pittsburgh Sleep Quality Index, with 65% above the cutoff of 5 indicating poor sleep quality in the previous 30 days. The melatonin-containing sleep lotion dramatically impacted salivary melatonin levels, increasing them up to ~1000 fold compared to the placebo control lotion. Sleep quality in the overall group was not impacted by the lotion, but in a subsample of the poor sleepers, the lotion improved sleep quality. High Performance Liquid Chromatography of the sleep lotion revealed the presence of 2.4 ± 0.1 mg melatonin/g lotion, or a 0.24 ± 0.01% formulation. Conclusion Caution should be taken by consumers using over-the-counter melatonin lotions because the undisclosed dosage is high and well absorbed by the skin. Clinicaltrials.gov ID NCT06053385 Support (if any)
neurosciences,clinical neurology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the effectiveness of telehealth cognitive - behavioral therapy for insomnia (telehealth CBTi) in improving insomnia symptoms in the elderly, especially by enhancing the treatment effect through applications (such as SleepSpace) that combine wearable devices and Internet of Things (IoT) technologies. Specifically, the study aims to compare the effects of three different interventions on insomnia symptoms: 1. **Sleep Hygiene Education** (Hygiene): Only provide knowledge education on sleep hygiene. 2. **Telehealth Cognitive - Behavioral Therapy for Insomnia** (CBTi): Conduct standard telehealth cognitive - behavioral therapy through video conferencing. 3. **Enhanced Telehealth Cognitive - Behavioral Therapy for Insomnia** (CBTi+): On the basis of CBTi, combine mobile phone applications and IoT platforms, provide functions such as meditation, sound machines, smart bulbs, electronic diaries, etc., and share with patients through visualization, indicators and wearable device data. The study recruited community - dwelling elderly aged 60 - 90 through a randomized controlled trial (RCT) design, using an Insomnia Severity Index (ISI) score of ≥11 as the enrollment criterion, and excluded participants with mild cognitive impairment. The main outcome measures were the rate of change in the ISI score, as well as the proportion of complete remission (ISI < 8) and self - reported sleep efficiency (sSE). The study results showed that the ISI scores in the CBTi and CBTi+ groups decreased significantly faster than in the Hygiene group, and the complete remission rate in the CBTi+ group was significantly higher than in the Hygiene group. In addition, the self - reported sleep efficiency in the CBTi+ group was also significantly better than that in the Hygiene group and the CBTi group. In conclusion, this study supports the effectiveness and feasibility of telehealth, technology - assisted cognitive - behavioral therapy in improving insomnia symptoms in the elderly, especially when combined with wearable devices and IoT technologies, which can provide more abundant data support and patient participation opportunities.